We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Biohaven Ltd. (BHVN - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Biohaven Ltd. is a member of the Medical sector. This group includes 1087 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Biohaven Ltd. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for BHVN's full-year earnings has moved 1.9% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that BHVN has returned about 109.3% since the start of the calendar year. At the same time, Medical stocks have lost an average of 9.2%. This shows that Biohaven Ltd. is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Blueprint Medicines (BPMC - Free Report) . The stock has returned 45.3% year-to-date.
In Blueprint Medicines' case, the consensus EPS estimate for the current year increased 6.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Biohaven Ltd. belongs to the Medical - Biomedical and Genetics industry, a group that includes 528 individual stocks and currently sits at #56 in the Zacks Industry Rank. On average, stocks in this group have lost 21.6% this year, meaning that BHVN is performing better in terms of year-to-date returns. Blueprint Medicines is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Biohaven Ltd. and Blueprint Medicines as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Biohaven Ltd. (BHVN - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Biohaven Ltd. is a member of the Medical sector. This group includes 1087 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Biohaven Ltd. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for BHVN's full-year earnings has moved 1.9% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that BHVN has returned about 109.3% since the start of the calendar year. At the same time, Medical stocks have lost an average of 9.2%. This shows that Biohaven Ltd. is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Blueprint Medicines (BPMC - Free Report) . The stock has returned 45.3% year-to-date.
In Blueprint Medicines' case, the consensus EPS estimate for the current year increased 6.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Biohaven Ltd. belongs to the Medical - Biomedical and Genetics industry, a group that includes 528 individual stocks and currently sits at #56 in the Zacks Industry Rank. On average, stocks in this group have lost 21.6% this year, meaning that BHVN is performing better in terms of year-to-date returns. Blueprint Medicines is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Biohaven Ltd. and Blueprint Medicines as they attempt to continue their solid performance.